SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Herantis Pharma Says New Clinical Evidence Validates HER-096 Phase 2 Design

Herantis Pharma says newly published clinical evidence validates the design of its HER-096 Phase 2 study.

Related stories